These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31346950)

  • 1. Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C.
    Costentin CE; Sogni P; Falissard B; Barbare JC; Bendersky N; Farges O; Goutte N
    Dig Dis Sci; 2020 Jan; 65(1):301-311. PubMed ID: 31346950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country.
    Goutté N; Sogni P; Bendersky N; Barbare JC; Falissard B; Farges O
    J Hepatol; 2017 Mar; 66(3):537-544. PubMed ID: 27773614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.
    Lewin M; Gelu-Simeon M; Ostos M; Boufassa F; Sobesky R; Teicher E; Meyer L; Fontaine H; Salmon-Céron D; Samuel D; Seror O; Trinchet JC; Duclos-Vallée JC
    Radiology; 2015 Nov; 277(2):443-53. PubMed ID: 25961631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?
    Edenvik P; Davidsdottir L; Oksanen A; Isaksson B; Hultcrantz R; Stål P
    Liver Int; 2015 Jul; 35(7):1862-71. PubMed ID: 25524812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
    Reddy SK; Steel JL; Chen HW; DeMateo DJ; Cardinal J; Behari J; Humar A; Marsh JW; Geller DA; Tsung A
    Hepatology; 2012 Jun; 55(6):1809-19. PubMed ID: 22183968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Analysis of Nonalcoholic Steatohepatitis- Versus Viral Hepatitis- and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma.
    Hester CA; Rich NE; Singal AG; Yopp AC
    J Natl Compr Canc Netw; 2019 Apr; 17(4):322-329. PubMed ID: 30959469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases.
    Fenoglio L; Serraino C; Castagna E; Cardellicchio A; Pomero F; Grosso M; Senore C
    World J Gastroenterol; 2013 Jun; 19(21):3207-16. PubMed ID: 23745022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome.
    Bucci L; Garuti F; Camelli V; Lenzi B; Farinati F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Maida M; Felder M; Morisco F; Gasbarrini A; Gemini S; Foschi FG; Missale G; Masotto A; Affronti A; Bernardi M; Trevisani F; ;
    Aliment Pharmacol Ther; 2016 Feb; 43(3):385-99. PubMed ID: 26662476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.
    Adhoute X; Pénaranda G; Raoul JL; Edeline J; Blanc JF; Pol B; Campanile M; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Le Treut YP; Bronowicki JP; Bourlière M
    World J Gastroenterol; 2017 Apr; 23(14):2545-2555. PubMed ID: 28465639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.
    Kim NG; Nguyen PP; Dang H; Kumari R; Garcia G; Esquivel CO; Nguyen MH
    Cancer; 2018 Jun; 124(12):2588-2598. PubMed ID: 29624631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors that affect risk for hepatocellular carcinoma and effects of surveillance.
    Yang JD; Harmsen WS; Slettedahl SW; Chaiteerakij R; Enders FT; Therneau TM; Orsini L; Kim WR; Roberts LR
    Clin Gastroenterol Hepatol; 2011 Jul; 9(7):617-23.e1. PubMed ID: 21459158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B- and C-endemic area.
    Huang YC; Huang CF; Chang KC; Hung SF; Wang JH; Hung CH; Chen CH; Tseng PL; Kee KM; Yen YH; Tsai PS; Tsai CC; Lu SN
    J Gastroenterol Hepatol; 2011 Jan; 26(1):129-34. PubMed ID: 21175806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort.
    Sinn DH; Gwak GY; Cho J; Paik SW; Yoo BC
    PLoS One; 2014; 9(11):e112184. PubMed ID: 25372403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
    J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does persistent anti-HBc positivity influence the prognosis of HBsAg-negative hepatocellular carcinoma? comparative outcomes of anti-Hbc positive versus anti-Hbc negative non-B non-C HCC.
    Law JH; Tan JKH; Wong KYM; Ng WQ; Tan PS; Bonney GK; Iyer SG; Krishnakumar M; Kow WCA
    HPB (Oxford); 2019 Feb; 21(2):242-248. PubMed ID: 30087053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic].
    Petry W; Heintges T; Hensel F; Erhardt A; Wenning M; Niederau C; Häussinger D
    Z Gastroenterol; 1997 Dec; 35(12):1059-67. PubMed ID: 9487638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
    Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
    Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular Carcinoma in a Tertiary Referral Hospital in Indonesia: Lack of Improvement of One-Year Survival Rates between 1998-1999 and 2013-2014.
    Loho IM; Hasan I; Lesmana CR; Dewiasty E; Gani RA
    Asian Pac J Cancer Prev; 2016; 17(4):2165-70. PubMed ID: 27221913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort.
    Gelu-Simeon M; Lewin M; Ostos M; Bayan T; Beso Delgado M; Teicher E; Layese R; Roudot-Thoraval F; Fontaine H; Sobesky R; Salmon-Céron D; Samuel D; Seror O; Nahon P; Meyer L; Duclos-Vallée JC;
    Liver Int; 2019 Jan; 39(1):136-146. PubMed ID: 29947467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.